Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemab Therapeutics HoldingsCOAG +3.48%11 Market Cap is $2,172.74 Mil as of Aug. 04, 2026. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Hemab Therapeutics Holdings ranks better than 89.18% on this metric.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hemab Therapeutics Holdings's Enterprise Value for Today is $2,010.27 Mil.
Hemab Therapeutics Holdings (NAS:COAG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hemab Therapeutics Holdings Market Cap Related Terms
Hemab Therapeutics Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings Market Cap Chart
Hemab Therapeutics Holdings Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Hemab Therapeutics Holdings Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
COAG vs ZLAB, SLS, IOVA: Market Cap Comparison
For the Biotechnology subindustry, Hemab Therapeutics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemab Therapeutics Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Hemab Therapeutics Holdings's Market Cap falls into.
Hemab Therapeutics Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings (COAG) has a Market Cap of $2,172.74 Mil as of Aug. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hemab Therapeutics Holdings and its competitors. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #154 out of 1423 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Hemab Therapeutics Holdings' Market Cap too high?
Hemab Therapeutics Holdings' current Market Cap is $2,172.74 Mil. The Biotechnology industry median Market Cap is 114.69. Hemab Therapeutics Holdings' value of $2,172.74 Mil is 1794.4% above this industry median. Based on the distribution chart, Hemab Therapeutics Holdings ranks #154 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Market Cap compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #154 out of 1423 companies for Market Cap. This places Hemab Therapeutics Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.69. Hemab Therapeutics Holdings' value of $2,172.74 Mil is 1794.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.69, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemab Therapeutics Holdings's current Market Cap of $2,172.74 Mil is 1794.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hemab Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 114.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemab Therapeutics Holdings's current Market Cap is $2,172.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Market Cap of $2,172.74 Mil. The current Market Cap is $2,172.74 Mil and 1794.4% above the Biotechnology industry median of 114.69. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Market Cap is $2,172.74 Mil as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score
Get the complete analysis for COAG
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COAG has been successfully added to your 
